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Abstract
q q  .The in vivo function of the erythrocyte Na –Li countertransport SLC is unknown. Whether SLC may reflect an
q q  .operational mode of the widespread Na –H exchanger NHE or may otherwise be expression of an independent
 .  .membrane transport, remains presently unclear. We explored the presence of 5- N, N-dimethyl -amiloride DMA -sensitive
Liq pathways in human erythrocytes where the activity of the Naq pump, Naq–Kq cotransport and anion exchange were
suitably inhibited. A total of 0.02 mM DMA had no effect on SLC as expected, but gave a significant inhibition of Liq
efflux into both Naq and Naq-free media. This DMA-sensitive Liq pathway, but not SLC, was significantly enhanced by
hyperosmolar cell shrinkage, which is a characteristic feature of NHE. In conclusion, DMA-sensitive Liq pathways,
possibly mediated by NHE, are present in erythrocytes and coexist with the DMA-insensitive, SLC. This finding supports
the notion that SLC is independent of amiloride-sensitive NHE. q 1998 Elsevier Science B.V.
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1. Introduction
q q  .Erythrocyte Na –Li countertransport SLC is a
long-known function of the erythrocyte membrane in
w xman and in several animal species 1,2 , but its nature
and role in physiology remain unclear. Naq–Hq
 .exchanger NHE activity is ubiquitous in human
tissues, where it can be mediated by one or more of
Abbreviations: SLC, erythrocyte Naq–Liq countertransport;
NHE, Naq–Hq exchanger; DIDS, 4,4X-diisothiocyanato-stilbene-
X  .2,2 -disulfonic acid; DMA, 5- N, N-dimethyl -amiloride; MOPS,
 .morpholino propane-sulfonic acid; BSA, bovine serum albumin
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w xseveral isoforms 3–5 , and is functionally detectable
w xalso in the erythrocyte 6–8 , where only the
amiloride-sensitive isoform NHE-1 appears to be de-
w x qtectable 9–11 . Studies of Na flux across the mem-
brane suggest that NHE may mediate a bidirectional
q q q w x1:1 exchange of Li for Na or H 12–15 , which
has contributed to the hypothesis that SLC may re-
w xflect an operational mode of this system 16,17 .
Furthermore, abnormal elevations of the NHE activ-
w xity are also found in essential hypertension 18–20
w xand in diabetic nephropathy 21–24 ; these findings
w xseems to parallel abnormally elevated SLC 22–25 .
However, SLC seems totally insensitive to
w xamiloride 26–29 , and the finding that the inter-indi-
vidual variability of SLC cannot be explained by
w xpolymorphisms of the gene encoding for NHE-1 30
appeared to favour the alternative view that SLC may
0005-2736r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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be mediated by a transmembrane carrier independent
w xof amiloride-sensitive transports 27,30 .
q q q q.Reversible exchange of Na or H for Na Li
is an established property of NHE in several kinds of
w xcells 12,13,31 . The erythrocyte seems, however, to
q q q. qlack a H -driven Na Li efflux, as external H in
q q. w xthis cell appears to inhibit Na Li efflux 32,33 ,
w xwhich is stimulated in other cells 12,13,31 . Interest-
ingly, intracellular Liq can activate NHE even at
w xresting intracellular pH 33 , and an amiloride-sensi-
tive Liq efflux pathway stimulated by hyperosmolar-
ity has been detected in Liq loaded canine erythro-
w xcytes and attributed to NHE 33 . Functional studies
aimed to detect the presence of amiloride-sensitive
Liq pathways across the erythrocyte membrane have
never been performed in humans.
Therefore, we explored the regulation of erythro-
cyte Liq efflux rates following challenge with spe-
cific inhibitors of SLC and NHE in isotonic media as
well as in hyperosmolar solutions, which are known
w xto enhance NHE 32,34,35 though not SLC activity
w x36 .
2. Materials and methods
Eleven healthy members of Hospital Staff gave
informed consent to participate in the study. A fasting
blood samples was drawn from the antecubital vein
from each individual and was processed within 2 h.
2.1. Reagents
Ouabain, bumetanide, 4,4X-diisothiocyanato-stil-
X  .  .bene-2,2 -disulfonic acid DIDS , 5- N, N-dimethyl -
 . amiloride DMA , nystatin, Me SO, Tris, morpho-2
.  .lino propane-sulfonic acid MOPS , bovine serum al-
 .bumin BSA , were purchased from Sigma Aldrich
 .Milan, Italy . LiCl monohydrate was purchased from
 .Merck Darmstadt, Germany . All other reagents and
 .chemicals were purchased from BDH Milan, Italy .
2.2. Erythrocyte Li efflux studies
Properties of erythrocyte Liq efflux were ad-
dressed following the original technique described by
w x w xCanessa et al. 37 and Canessa 38 , as subsequently
modified by the use of nystatin to load cells with Liq
w x39 . In brief, after the removal of plasma and buffy
coat, washed erythrocytes were incubated for 20 min
at 48C in an unbuffered solution containing 40 mg
mly1 of nystatin, 50 mM sucrose, 130 mM KCl and
20 mM LiCl, followed by centrifugation and resus-
pension of the cell pellet for 10 min in the same
solution, though without nystatin. The ionophore was
removed by washing cells for four times at 378C in a
 .1 mM K-phosphate buffer pH 7.4 containing 50
mM sucrose, 130 mM KCl, 20 mM LiCl, 10 mM
glucose and 1 mg ly1 BSA. External Liq was then
removed by washing erythrocytes for four times at
 .48C, in a neutral pH 7.4 10 mM Tris–MOPS buffer
containing 150 mM choline–Cl and 1.0 mM MgCl .2
The osmolarity of these solutions was always ad-
justed to range between 300 and 310 mosM. Liq-
loaded erythrocytes were finally resuspended in cold
washing buffer; aliquots from each individual were
transferred into full set of efflux media, suitably
matching a hematocrit of 3–4% in each efflux incu-
bate.
q  q .Na and choline Na -free efflux media were
 .isotonic and neutral pH 7.4 at 378C . These con-
tained either 150 mM NaCl, or equimolar choline–Cl,
in 10 mM Tris–MOPS buffer with 10 mM glucose
 .and 1.0 mM MgCl . Ouabain 0.1 mM , 0.1 mM2
bumetanide and 0.2 mM DIDS were always added to
block, respectively, the activity of the Naq pump,
q q w xNa –K cotransport and anion exchanger 40–43 .
To study Liq efflux, experiments were carried out
in parallel incubates with or without the presence of
20 mM DMA andror 200 mM phloretin.
To induce hyperosmotic shrinkage of erythrocytes,
both efflux media were made hypertonic by adding
200 mM sucrose, to obtain a final osmolarity of
500–510 mosM. Under these conditions, the mean
corpuscular volume can be reduced by 30"1.7%. To
minimize the effect of inter-assay variability, erythro-
cytes from each individual were always tested with a
full set of efflux media within a single experiment.
Duplicate aliquots of each incubate were taken at
the beginning of the incubation and after 15 and 30
min at 378C, were chilled in melting ice and cen-
trifuged at 48C. Supernatants were taken for the
measurement of Liq concentrations by atomic ab-
 .sorption spectrophotometry Perkin Elmer 4000 .
Liq efflux rates were calculated in each medium
as the change in Liq concentration over time by
simple linear regression analysis, and expressed as
( )G. Zerbini et al.rBiochimica et Biophysica Acta 1371 1998 129–133 131
mmol ly1 hy1. The correlation coefficient was highercell
than 0.98 in all studies. As usual, SLC was taken as
the difference between Liq efflux rates in Naq and
choline media. The response of Liq efflux to hyper-
osmolar cell shrinkage andror DMA was evaluated
both in Naq and in choline media by calculating
relevant differences in Liq efflux rates.
2.3. Statistical analysis
Data are shown as arithmetical mean with standard
error. Comparisons between paired or observations
were addressed by Student’s t-test. Correlations were
sought by simple linear regression. The null hypothe-
sis was rejected for two-tailed P values less than
5%.
3. Results
SLC ranged between 164 and 783 mmol ly1 hy1cell
 .mean"S.E.: 360"53 in the 11 healthy individuals
Fig. 1. Upper panel. Effect of DMA on Liq efflux from Liq-
 . qloaded erythrocytes into choline ) P s0.001 or Na media
 .)) P s0.002 , ns11. Lower panel. Effect of DMA on SLC
 .activity P sns , ns11.
Fig. 2. Upper panel. Effect of hyperosmotic cell shrinkage on
 .SLC activity P sns , ns11. Lower panel. Effect of hyperos-
motic cell shrinkage on the DMA-sensitive component of Liq
 .efflux in choline medium P s0.005 , ns11.
considered for these studies. Liq efflux into Naq-free
media, was 345"28 mmol ly1 hy1 and was signifi-cell
 .cantly inhibited to 243"13 Ps0.001 in the pres-
ence of DMA. However, total Liq efflux into Naq
media was comparably inhibited from 705"71 to
595"49 mmol ly1 hy1 in the presence of DMAcell
 .  .Ps0.002 , leaving SLC unchanged Fig. 1 . In line
with these observations, DMA-sensitive components
of Liq efflux in Naq media were highly correlated
q  2with those measured in Na -free media R s0.83,
.P-0.0001 , and standard SLC was likewise related
with SLC as calculated in the presence of DMA
 2R s0.92, b-coefficient"S.E.: 1.07"0.10, P-
. q0.0001 . The DMA sensitive component of Li leak
was unrelated with the complementary DMA-insensi-
 2 .tive component R s0.16, Psns ; there was a
weak positive association with SLC that missed sta-
 2 .tistical significance R s0.31, Ps0.07 . Phloretin
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significantly inhibited SLC from 360"53 to 64.7"
y1 y1 .12 mmol l h , P-0.0005 .cell
Hyperosmolar shrinkage of erythrocytes induced
significant but parallel increases in Liq efflux both
q  y1into Na from 705"71 to 995"122 mmol lcell
y1 . h , Ps0.0011 and into choline media from 345
y1 y1 ."28 to 668"81 mmol l h , Ps0.0002 , leav-cell
ing again SLC unchanged 327"48 vs. standard
.SLC, Psns and strongly correlated with standard
 2SLC R s0.87, b-coefficient"S.E.s1.01"0.12,
. qP-0.0001 . The DMA-sensitive component in Li
efflux was increased by hyperosmotic shrinkage, both
 y1in choline from 110"21 to 282"67 mmol lcell
y1 . q h , Ps0.005, Fig. 2 and in Na media from
.109"31 to 328"26, Ps0.003 . Phloretin inhib-
ited the SLC also after hyperosmotic shrinkage from
y1 y1 .327"48 to 48.0"12 mmol l h , P-0.0005 .cell
4. Discussion
The present study extends the concept that SLC is
entirely insensitive to amiloride in human erythro-
w xcytes 26–29 , but can be largely inhibited by
w xphloretin in all individuals 2,26,44 . Furthermore, we
describe for the first time in human erythrocytes a
SLC-independent, DMA-sensitive component of Liq
efflux that can be activated by hyperosmolar cell
shrinkage, which is a known stimulus of NHE
w x q32,34,35 . Evidence that such a component of Li
efflux may be mediated by NHE has not been di-
rectly provided by the present study, but the demon-
stration of DMA-sensitivity and the possibility to
enhance its magnitude by hyperosmolar cell shrink-
age is consistent with this view. In contrast, SLC
failed to increase its activity under hyperosmolar
w xconditions, in line with previous evidence 36 .
While emphasizing the independence of SLC from
amiloride-sensitive fluxes, the possibility that
amiloride-insensitive and as yet undefined isoforms
of NHE may be present in erythrocytes cannot be
entirely ruled out. Amiloride-insensitive NHE has
w xbeen reported in other cells 45–47 raising the possi-
bility that SLC maybe mediated by a similar carrier.
However, while sensitivity to phloretin is an invari-
w xable feature of SLC 2,26,44 , this property does not
characterize the amiloride-insensitive NHE of human
w xthymic lymphocytes 45 . A second amiloride-insensi-
tive NHE was described in rat hippocampal synapto-
some preparations and could be inhibited by harma-
w xline 46 , that fails however to inhibit SLC in our
 .laboratory unpublished observation . Taken together,
these observations further reduce the possibility that
SLC may reflect an operational mode of amiloride-
sensitive NHE isoforms, leaving its nature and role in
physiology open to speculation. It has been suggested
that SLC operates a futile Naq–Naq exchange in
vivo, but the presence of such an exchange is contro-
w xversial in human erythrocytes 48,49 . A third possi-
bility is that SLC may just represent a degraded
remnant with no physiologic role in the circulating
mature cell.
Based on the finding of parallel differences in
NHE and SLC activity rates in essential hypertension
and diabetic nephropathy, a correlation between the
V of NHE and that of SLC has been suggested inmax
w xerythrocytes 25,50 . This may be in line with the
sharing of one or more regulatory pathways, although
w xthis correlation was not found by other authors 19 .
Our suggestion that SLC is independent of
amiloride-sensitive membrane transports appears to
encourage a better definition of the mechanisms that
w xunderlie its elevated rates in human disease 51–54
and the search for a candidate SLC gene in essential
w x w xhypertension 55 andror diabetic nephropathy 56 .
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